文献速递浆细胞疾病

甲羟戊酸通路是t(4;14)阳性多发性骨髓瘤的可干预脆弱点

The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
PubMed 文献 · Leukemia · 2020-07-14

本研究显示t(4;14)阳性多发性骨髓瘤细胞高度依赖甲羟戊酸(MVA)通路生存,他汀抑制该通路可优先诱导t(4;14)阳性细胞凋亡。他汀处理激活整合应激反应(ISR),与硼替佐米联用可增强ISR并协同诱导凋亡;外源性GGPP可完全逆转他汀所致ISR激活和凋亡。氟伐他汀与硼替佐米协同并在体内增强硼替佐米抗肿瘤活性,提示t(4;14)可作为他汀敏感性生物标志物,需进一步临床评估他汀联合硼替佐米治疗t(4;14)阳性疾病。

要点

  • t(4;14)阳性多发性骨髓瘤细胞高度依赖甲羟戊酸通路生存。
  • 他汀抑制甲羟戊酸通路优先诱导t(4;14)阳性细胞凋亡。
  • 外源性GGPP完全逆转他汀诱导的ISR激活和凋亡。

核心结论

  • t(4;14)阳性多发性骨髓瘤细胞高度依赖甲羟戊酸通路生存,他汀抑制该通路可优先诱导t(4;14)阳性细胞凋亡。
  • t(4;14)阳性细胞依赖甲羟戊酸通路合成GGPP,外源性GGPP可完全逆转他汀诱导的ISR激活和凋亡。
  • 氟伐他汀与硼替佐米协同诱导t(4;14)阳性细胞凋亡,并在体内增强硼替佐米抗肿瘤活性。
  • 数据提示t(4;14)易位可作为他汀敏感性生物标志物,需进一步临床评估他汀联合硼替佐米治疗t(4;14)阳性疾病。

研究设计与样本

  • 原文未报告研究设计与样本量。

主要发现

  • t(4;14)阳性细胞高度依赖甲羟戊酸通路生存。
  • 他汀抑制甲羟戊酸通路优先诱导t(4;14)阳性细胞凋亡。
  • 他汀处理使t(4;14)阳性细胞激活ISR,与硼替佐米共处理可增强该反应。
  • 外源性GGPP完全逆转他汀诱导的ISR激活和凋亡。
  • 抑制蛋白香叶基香叶基化同样诱导t(4;14)阳性细胞ISR。

临床怎么用

  • 作者认为t(4;14)易位可作为他汀敏感性生物标志物。
  • 作者提出需进一步临床评估他汀联合硼替佐米治疗t(4;14)阳性疾病。

局限性

  • 原文结论指出需进一步临床评估他汀联合硼替佐米治疗t(4;14)阳性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a plasma cell malignancy that is often driven by chromosomal translocations. In particular, patients with t(4;14)-positive disease have worse prognosis compared to other MM subtypes. Herein, we demonstrated that t(4;14)-positive cells are highly dependent on the mevalonate (MVA) pathway for survival. Moreover, we showed that this metabolic vulnerability is immediately actionable, as inhibiting the MVA pathway with a statin preferentially induced apoptosis in t(4;14)-positive cells. In response to statin treatment, t(4;14)-positive cells activated the integrated stress response (ISR), which was augmented by co-treatment with bortezomib, a proteasome inhibitor. We identified that t(4;14)-positive cells depend on the MVA pathway for the synthesis of geranylgeranyl pyrophosphate (GGPP), as exogenous GGPP fully rescued statin-induced ISR activation and apoptosis. Inhibiting protein geranylgeranylation similarly induced the ISR in t(4;14)-positive cells, suggesting that this subtype of MM depends on GGPP, at least in part, for protein geranylgeranylation. Notably, fluvastatin treatment synergized with bortezomib to induce apoptosis in t(4;14)-positive cells and potentiated the anti-tumor activity of bortezomib in vivo. Our data implicate the t(4;14) translocation as a biomarker of statin sensitivity and warrant further clinical evaluation of a statin in combination with bortezomib for the treatment of t(4;14)-positive disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Longo J, Smirnov P, Li Z, et al. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia. 2020. PMID: 32665698. doi:10.1038/s41375-020-0962-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。